{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:13:49Z","timestamp":1761905629908,"version":"build-2065373602"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Community pharmacists are the most publicly accessible health professionals in high-income countries. There is increasing interest in conducting randomised controlled trials (RCT)\u2014the benchmark of original evidence in the medical field\u2014in community pharmacies. However, little evidence exists examining the challenges and opportunities of conducting RCTs in pharmacies, particularly with respect to project management. In this work, we aim to provide a narrative of lessons learned in conducting two RCTs in community pharmacies in two high-income countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed multiple data sources including administrative and trial activity records. We conducted face-to-face and online sessions to create a list of lessons learned from our experiences and created a stakeholder map for the trials examined. We framed our findings using the Project Managements Institute\u2019s model of the project life cycle, and descriptive statistics were used to estimate the outcomes reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-six pharmacies were recruited. Across the project phases, seven high-level tasks within Initiation; 30 within Planning, 43 within Execution\/Monitoring and Controlling, and 14 in Closure, were identified. Recruitment of pharmacies, developing documentation for trial drug supply, participant recruitment, and negotiation with pharmacy contracting bodies took longest to complete. Eight key stakeholder groups were identified, including public services\/agencies; community pharmacies, communications actors; funders\/sponsors; universities\/research institutes; healthcare providers; suppliers; and regulators. Thirty lessons were identified, most critically across engaging and managing stakeholders; selecting and supporting trial sites; streamlining trial processes to minimise burden; optimising data collection and accuracy; and considering pharmacy constraints and costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Conducting RCTs in community pharmacies presents unique challenges across the project life cycle. Key lessons include the importance of early planning, streamlining processes to reduce staff burden, and addressing pharmacy constraints. The complexity of the work necessitates dedicated and well-resourced trial management staff to enhance stakeholder management and offer tailored supports where required.<\/jats:p>\n                    <jats:p>Trial registration.<\/jats:p>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09196-9","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:11:29Z","timestamp":1761905489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lessons learned from two multicentre randomised controlled trials undertaken in pharmacies in community settings: a retrospective project management analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Christopher J.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah K.","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Radley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis J.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh D.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Allardice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicki","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"9196_CR1","first-page":"1341","volume":"12","author":"PM Spieth","year":"2016","unstructured":"Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T. Randomized controlled trials - a matter of design. Neuropsychiatr Dis Treat. 2016;12:1341\u20139.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"9196_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/emj.20.2.164","volume":"20","author":"JM Kendall","year":"2003","unstructured":"Kendall JM. Designing a research project: randomised controlled trials and their principles. Emerg Med J. 2003;20(2):164\u20138.","journal-title":"Emerg Med J"},{"issue":"1","key":"9196_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06348-z","volume":"23","author":"S Treweek","year":"2022","unstructured":"Treweek S, Miyakoda V, Burke D, Shiely F. Getting it wrong most of the time? Comparing trialists\u2019 choice of primary outcome with what patients and health professionals want. Trials. 2022;23(1):537.","journal-title":"Trials"},{"issue":"7","key":"9196_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014796","volume":"7","author":"A Hurtado-Chong","year":"2017","unstructured":"Hurtado-Chong A, Joeris A, Hess D, Blauth M. Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results. BMJ Open. 2017;7(7):e014796.","journal-title":"BMJ Open"},{"key":"9196_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156\u201364.","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"9196_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/26320843221106950","volume":"4","author":"A Parker","year":"2023","unstructured":"Parker A, Arundel C, Mills N, Rooshenas L, Jepson M, Donovan JL, et al. Staff training to improve participant recruitment into surgical randomised controlled trials: a feasibility study within a trial (SWAT) across four host trials simultaneously. Research Methods in Medicine & Health Sciences. 2023;4(1):2\u201315.","journal-title":"Research Methods in Medicine & Health Sciences"},{"issue":"1","key":"9196_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06223-x","volume":"23","author":"E Murphy","year":"2022","unstructured":"Murphy E, Shiely F, Treweek S. How much is the lack of retention evidence costing trial teams in Ireland and the UK? Trials. 2022;23(1):396.","journal-title":"Trials"},{"key":"9196_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-32","volume":"15","author":"C Tudur Smith","year":"2014","unstructured":"Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson P. The trials methodological research agenda: results from a priority setting exercise. Trials. 2014;15:32.","journal-title":"Trials"},{"issue":"1","key":"9196_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05818-0","volume":"22","author":"M Briel","year":"2021","unstructured":"Briel M, Elger BS, McLennan S, Schandelmaier S, von Elm E, Satalkar P. Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada. Trials. 2021;22(1):844.","journal-title":"Trials"},{"key":"9196_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2019.06.016","volume":"115","author":"AE Young","year":"2019","unstructured":"Young AE, Brookes ST, Avery KNL, Davies A, Metcalfe C, Blazeby JM. A systematic review of core outcome set development studies demonstrates difficulties in defining unique outcomes. J Clin Epidemiol. 2019;115:14\u201324.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"9196_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4139-0","volume":"21","author":"J He","year":"2020","unstructured":"He J, Morales DR, Guthrie B. Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review. Trials. 2020;21(1):228.","journal-title":"Trials"},{"issue":"1","key":"9196_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06973-8","volume":"23","author":"H Gardner","year":"2022","unstructured":"Gardner H, Elfeky A, Pickles D, Dawson A, Gillies K, Warwick V, et al. A good use of time? Providing evidence for how effort is invested in primary and secondary outcome data collection in trials. Trials. 2022;23(1):1047.","journal-title":"Trials"},{"key":"9196_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1870-2","author":"C Heneghan","year":"2017","unstructured":"Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017. https:\/\/doi.org\/10.1186\/s13063-017-1870-2.","journal-title":"Trials"},{"issue":"4","key":"9196_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003980","volume":"19","author":"B Speich","year":"2022","unstructured":"Speich B, Gryaznov D, Busse JW, Gloy VL, Lohner S, Klatte K, et al. Nonregistration, discontinuation, and nonpublication of randomized trials: a repeated metaresearch analysis. PLoS Med. 2022;19(4):e1003980.","journal-title":"PLoS Med"},{"key":"9196_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-11-78","volume":"11","author":"B Farrell","year":"2010","unstructured":"Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials. 2010;11:78.","journal-title":"Trials"},{"key":"9196_CR16","unstructured":"UK Trial Managers' Network (UKTMN). The Guide to Efficient Trial Management. 2018. https:\/\/hubble-live-assets.s3.amazonaws.com\/uktmn\/redactor2_assets\/files\/4\/UKTMNG2.web.pdf."},{"issue":"3","key":"9196_CR17","first-page":"21","volume":"10","author":"LC Stuckenbruck","year":"1979","unstructured":"Stuckenbruck LC. The matrix organization. Project Management Quarterly. 1979;10(3):21\u201333.","journal-title":"Project Management Quarterly"},{"key":"9196_CR18","unstructured":"Baratta A. The triple constraint: a triple illusion. PMI Global Congress; North America, Seattle, WA: Project Management Institute; 2006.\u00a0https:\/\/www.pmi.org\/learning\/library\/triple-constraint-erroneous-useless-value-8024."},{"issue":"8","key":"9196_CR19","volume":"10","author":"C Byrne","year":"2020","unstructured":"Byrne C, Radley A, Inglis SK, Beer LJZ, Palmer N, Pham MD, et al. Reaching methadone users attending community pharmacies with HCV: an international cluster randomised controlled trial protocol BMJ Open. 2020;10(8):e036501.","journal-title":"Reaching methadone users attending community pharmacies with HCV: an international cluster randomised controlled trial protocol BMJ Open"},{"issue":"12","key":"9196_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021443","volume":"8","author":"A Radley","year":"2018","unstructured":"Radley A, de Bruin M, Inglis SK, Donnan PT, Dillon JF. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. BMJ Open. 2018;8(12):e021443.","journal-title":"BMJ Open"},{"key":"9196_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2018.12.008","volume":"65","author":"A Radley","year":"2019","unstructured":"Radley A, van der Pol M, Dillon JF. Application of a discrete choice experiment approach to support the design of a hepatitis C testing service in primary care. Int J Drug Policy. 2019;65:1\u20137.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"9196_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029538","volume":"9","author":"M Hickman","year":"2019","unstructured":"Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, et al. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). BMJ Open. 2019;9(9):e029538.","journal-title":"BMJ Open"},{"issue":"12","key":"9196_CR23","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/apt.16953","volume":"55","author":"CJ Byrne","year":"2022","unstructured":"Byrne CJ, Radley A, Inglis SK, Beer L, Palmer N, Duc Pham M, et al. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial. Aliment Pharmacol Ther. 2022;55(12):1512\u201323.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9196_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/apt.16728","volume":"55","author":"CJ Byrne","year":"2022","unstructured":"Byrne CJ, Beer L, Inglis SK, Robinson E, Radley A, Goldberg DJ, et al. Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland. Aliment Pharmacol Ther. 2022;55(5):568\u201379.","journal-title":"Aliment Pharmacol Ther"},{"key":"9196_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14911-1","author":"E Robinson","year":"2023","unstructured":"Robinson E, Byrne CJ, Carberry J, Radley A, Beer LJ, Inglis SK, et al. Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts. BMC Public Health. 2023. https:\/\/doi.org\/10.1186\/s12889-022-14911-1.","journal-title":"BMC Public Health"},{"key":"9196_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14015","author":"JF Ginnane","year":"2024","unstructured":"Ginnane JF, Scott N, Radley A, Dillon JF, Hellard M, Doyle J. Cost-effectiveness of treating Hepatitis C in clients on opioid agonist therapy in community pharmacies compared to primary healthcare in Australia. J Viral Hepat. 2024. https:\/\/doi.org\/10.1111\/jvh.14015.","journal-title":"J Viral Hepat"},{"key":"9196_CR27","doi-asserted-by":"crossref","unstructured":"Ong E, Xia T, Laing R, Richmond JA, Higgs P, Hayes M, et al. Australian Community Pharmacists\u2019 Preparedness to Offer and Discuss Hepatitis C Testing and Treatment With Pharmacy Clients: A Representative Cross\u2010Sectional Survey. J Viral Hepat. 2025;32(2).","DOI":"10.1111\/jvh.70001"},{"key":"9196_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102489","volume":"69","author":"MJ Hayes","year":"2024","unstructured":"Hayes MJ, Beavon E, Traeger MW, Dillon JF, Radley A, Nielsen S, et al. Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis. EClinicalMedicine. 2024;69:102489.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"9196_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","volume":"5","author":"A Radley","year":"2020","unstructured":"Radley A, de Bruin M, Inglis SK, Donnan PT, Hapca A, Barclay ST, et al. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020;5(9):809\u201318.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9196_CR30","unstructured":"Scottish Government. Achieving excellence in pharmaceutical care: a strategy for Scotland 2017 [updated 21\/08\/2017. Available from: https:\/\/www.gov.scot\/publications\/achieving-excellence-pharmaceutical-care-strategy-scotland\/."},{"key":"9196_CR31","unstructured":"Australian Government. Unleashing the Potential of our Health Workforce \u2013 Scope of Practice Review Final Report 2024 [updated 05\/11\/2024. Available from: https:\/\/www.health.gov.au\/resources\/publications\/unleashing-the-potential-of-our-health-workforce-scope-of-practice-review-final-report."},{"key":"9196_CR32","unstructured":"Sayburn A. Should community pharmacists get involved in research? : Chemist and Druggist; 2017 [updated 07\/07\/2017. Available from: https:\/\/www.chemistanddruggist.co.uk\/CD004936\/Should-community-pharmacists-get-involved-in-research\/."},{"key":"9196_CR33","unstructured":"Royal Pharmaceutical Society. Research & Evaluation 2017 [updated 31\/03\/2017. Available from: https:\/\/www.rpharms.com\/development\/research-and-evaluation\/guidance-and-support-for-research."},{"key":"9196_CR34","unstructured":"Australian Government. Pharmacy Trial Program 2023 [updated 21\/09\/2023. Available from: https:\/\/www.health.gov.au\/our-work\/pharmacy-trial-program."},{"key":"9196_CR35","unstructured":"Tayside Clinical Trials Unit (TCTU). TCTU trial process: Timeline of the clinical trial process followed by TCTU 2023 [updated 10\/01\/2023. Available from: https:\/\/www.dundee.ac.uk\/tctu\/trial-process."},{"key":"9196_CR36","unstructured":"ClinicalTrials.gov. Testing and Treating Hepatitis C in Community Pharmacies (SuperDOT-C): NIH US National Library of Medicine; 2016 [updated 30\/08\/2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02706223."},{"key":"9196_CR37","unstructured":"ClinicalTrials.gov. Reaching methadone users attending community pharmacies with HCV (REACH HCV): NIH US National Library of Medicine; 2019 [updated 13\/10\/2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03935906."},{"key":"9196_CR38","unstructured":"University of Dundee. Tayside Clinical Trials Unit (TCTU) 2020 [Available from: https:\/\/www.dundee.ac.uk\/tctu."},{"key":"9196_CR39","unstructured":"Project Management Institute. A Guide to the Project Management Body of Knowledge (PMBOK Guide) and The Standard for Project Management. 7th ed. Pennsylvania: Project Management Institute; 2021. ISBN 978-1-62825-664-2."},{"issue":"1","key":"9196_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3634-7","volume":"20","author":"DS McCaskell","year":"2019","unstructured":"McCaskell DS, Molloy AJ, Childerhose L, Costigan FA, Reid JC, McCaughan M, et al. Project management lessons learned from the multicentre CYCLE pilot randomized controlled trial. Trials. 2019;20(1):532.","journal-title":"Trials"},{"key":"9196_CR41","unstructured":"MatchWare. MindView by MatchWare 2022 [Available from: https:\/\/www.matchware.com\/mind-mapping-software."},{"issue":"3","key":"9196_CR42","doi-asserted-by":"publisher","DOI":"10.2196\/27921","volume":"11","author":"JR Turek","year":"2022","unstructured":"Turek JR, Bansal V, Tekin A, Singh S, Deo N, Sharma M, et al. Lessons from a rapid project management exercise in the time of pandemic: methodology for a global COVID-19 virus registry database. JMIR Res Protoc. 2022;11(3):e27921.","journal-title":"JMIR Res Protoc"},{"issue":"10","key":"9196_CR43","doi-asserted-by":"publisher","DOI":"10.2196\/26266","volume":"5","author":"J Woodford","year":"2021","unstructured":"Woodford J, Karlsson M, Hagstrom J, Hagg Sylven Y, Norback K, Gronqvist H, et al. Conducting digital health care research: document analysis of challenges experienced during intervention development and feasibility study setup of an internet-administered intervention for parents of children treated for cancer. JMIR Form Res. 2021;5(10):e26266.","journal-title":"JMIR Form Res"},{"issue":"1","key":"9196_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-021-02248-0","volume":"21","author":"D Dash","year":"2021","unstructured":"Dash D, Schumacher C, Jones A, Costa AP. Lessons learned implementing and managing the DIVERT-CARE trial: practice recommendations for a community-based chronic disease self-management model. BMC Geriatr. 2021;21(1):303.","journal-title":"BMC Geriatr"},{"issue":"1","key":"9196_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2765-6","volume":"19","author":"C Arundel","year":"2018","unstructured":"Arundel C, Gellatly J. Learning from OCTET - exploring the acceptability of clinical trials management methods. Trials. 2018;19(1):378.","journal-title":"Trials"},{"key":"9196_CR46","unstructured":"National Institute for Health and Care Research (NIHR). Research Inclusion Strategy 2022\u20132027 2022 [updated 26\/09\/2022. Available from: https:\/\/www.nihr.ac.uk\/about-us\/who-we-are\/research-inclusion\/strategy-2022-27."},{"key":"9196_CR47","unstructured":"National Institutes of Health. Review of the Literature: Primary Barriers and Facilitators to Participation in Clinical Research 2015 [updated 19\/10\/2015. Available from: https:\/\/orwh.od.nih.gov\/sites\/orwh\/files\/docs\/orwh_outreach_toolkit_litreview.pdf."},{"issue":"8","key":"9196_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005764","volume":"4","author":"A Todd","year":"2014","unstructured":"Todd A, Copeland A, Husband A, Kasim A, Bambra C. The positive pharmacy care law: an area-level analysis of the relationship between community pharmacy distribution, urbanity and social deprivation in England. BMJ Open. 2014;4(8):e005764.","journal-title":"BMJ Open"},{"key":"9196_CR49","unstructured":"Edelman. Edelman Trust Barometer Special Report 2023 [updated 20\/04\/2023. Available from: https:\/\/www.edelman.com\/sites\/g\/files\/aatuss191\/files\/2023-04\/2023%20Edelman%20Trust%20Barometer%20Trust%20and%20Health1.pdf."},{"key":"9196_CR50","unstructured":"Stent J. Pharmacists more trusted than doctors, UK-wide survey finds: Chemist and Druggist; 2023 [updated 09\/06\/2023. Available from: https:\/\/www.chemistanddruggist.co.uk\/CD137066\/Pharmacists-more-trusted-than-doctors-UKwide-survey-finds\/."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09196-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09196-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09196-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:11:34Z","timestamp":1761905494000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09196-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9196"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09196-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable: this work did not require human or animal ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable: not participants were recruited to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CJB reports honoraria from the International Network for Health and Hepatitis in Drugs Users (INHSU) and research funding from the Scottish Society of Physicians (SSP) outside of the submitted work. SKI reports no competing interests. AR reports he has received research grants from Gilead, Bristol Myers Squibb, Abbvie and Roche and has received honorariums from Gilead and personal fees from Abbvie. LJB reports grants from NIHR outside the submitted work. MDP reports no competing interests. KA reports no competing interests. NP reports no competing interests. BH reports personal fees and other from Abbvie, personal fees and other from Gilead, outside the submitted work. JSD reports funding to his institution for investigator-initiated research from Gilead Sciences and Abbvie; and honoraria to his institution for educational events from AbbVie. JFD has received research grants and lecture honoraria from MSD, AbbVie and Gilead, outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"461"}}